118 related articles for article (PubMed ID: 17329879)
1. Indoline derivatives II: synthesis and factor Xa (FXa) inhibitory activities.
Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Ozeki T; Fujimoto K
Chem Pharm Bull (Tokyo); 2007 Mar; 55(3):393-402. PubMed ID: 17329879
[TBL] [Abstract][Full Text] [Related]
2. Cinnamylindoline derivatives: synthesis and factor Xa (FXa) inhibitory activities.
Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K
Chem Pharm Bull (Tokyo); 2007 Oct; 55(10):1494-504. PubMed ID: 17917295
[TBL] [Abstract][Full Text] [Related]
3. Discovery of R-142086 as a factor Xa (FXa) inhibitor: syntheses and structure-activity relationships of cinnamyl derivatives.
Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Niitsu Y; Asai F; Ishizuka T; Fujimoto K
Chem Pharm Bull (Tokyo); 2009 Jan; 57(1):22-33. PubMed ID: 19122312
[TBL] [Abstract][Full Text] [Related]
4. Indoline derivatives I: synthesis and factor Xa (FXa) inhibitory activities.
Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Matsui Y; Fujimoto K
Chem Pharm Bull (Tokyo); 2006 Feb; 54(2):163-74. PubMed ID: 16462058
[TBL] [Abstract][Full Text] [Related]
5. Cinnamyl derivatives: synthesis and factor Xa (FXa) inhibitory activities.
Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K
Chem Pharm Bull (Tokyo); 2008 Jun; 56(6):758-70. PubMed ID: 18520077
[TBL] [Abstract][Full Text] [Related]
6. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
Nagahara T; Yokoyama Y; Inamura K; Katakura S; Komoriya S; Yamaguchi H; Hara T; Iwamoto M
J Med Chem; 1994 Apr; 37(8):1200-7. PubMed ID: 8164262
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors.
Huang C; Wang W; Li Y; Zhang S; Meng F; Xu W; Yuan J; Chen L
Oncotarget; 2017 Jun; 8(23):37186-37199. PubMed ID: 28415603
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
Sun X; Hong Z; Liu M; Guo S; Yang D; Wang Y; Lan T; Gao L; Qi H; Gong P; Liu Y
Bioorg Med Chem; 2017 May; 25(10):2800-2810. PubMed ID: 28389110
[TBL] [Abstract][Full Text] [Related]
9. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors.
Zhao Y; Jiang M; Zhou S; Wu S; Zhang X; Ma L; Zhang K; Gong P
Eur J Med Chem; 2015; 96():369-80. PubMed ID: 25911624
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.
Hirayama F; Koshio H; Ishihara T; Watanuki S; Hachiya S; Kaizawa H; Kuramochi T; Katayama N; Kurihara H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2002 Aug; 10(8):2597-610. PubMed ID: 12057649
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors.
Arnaiz DO; Zhao Z; Liang A; Trinh L; Witlow M; Koovakkat SK; Shaw KJ
Bioorg Med Chem Lett; 2000 May; 10(9):957-61. PubMed ID: 10853668
[TBL] [Abstract][Full Text] [Related]
13. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.
Furugohri T; Isobe K; Honda Y; Kamisato-Matsumoto C; Sugiyama N; Nagahara T; Morishima Y; Shibano T
J Thromb Haemost; 2008 Sep; 6(9):1542-9. PubMed ID: 18624979
[TBL] [Abstract][Full Text] [Related]
14. The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.
Hirayama F; Koshio H; Katayama N; Kurihara H; Taniuchi Y; Sato K; Hisamichi N; Sakai-Moritani Y; Kawasaki T; Matsumoto Y; Yanagisawa I
Bioorg Med Chem; 2002 May; 10(5):1509-23. PubMed ID: 11886813
[TBL] [Abstract][Full Text] [Related]
15. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids.
Sagi K; Nakagawa T; Yamanashi M; Makino S; Takahashi M; Takayanagi M; Takenaka K; Suzuki N; Oono S; Kataoka N; Ishikawa K; Shima S; Fukuda Y; Kayahara T; Takehana S; Shima Y; Tashiro K; Yamamoto H; Yoshimoto R; Iwata S; Tsuji T; Sakurai K; Shoji M
J Med Chem; 2003 May; 46(10):1845-57. PubMed ID: 12723948
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of the metabolites of 2-(1-{3-[(6-chloronaphthalen-2-yl)sulfonyl]propanoyl}piperidin-4-yl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one.
Fujimoto T; Tobisu M; Konishi N; Kawamura M; Tada N; Takagi T; Kubo K
Bioorg Med Chem; 2009 Dec; 17(23):7993-8002. PubMed ID: 19861238
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template.
Hirayama F; Koshio H; Katayama N; Ishihara T; Kaizawa H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kurihara H; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2003 Feb; 11(3):367-81. PubMed ID: 12517432
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
[TBL] [Abstract][Full Text] [Related]
20. Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa.
Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Nagamochi M; Kobayashi S; Komoriya S; Yokomizo A; Muto R; Yamaguchi M; Osanai K; Suzuki M; Kanno H
Bioorg Med Chem; 2009 Feb; 17(3):1193-206. PubMed ID: 19128974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
